Retrospective Analysis of Brachytherapy and Stereotactic Body Radiotherapy in Patients with Cholangiocarcinoma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00037599

Enrollment

Registered

2025-08-15

Start date

2025-07-15

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C22.1

Interventions

Group 1: Patients who underwent brachytherapy or stereotactic body radiotherapy for cholangiocarcinoma.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Histologically or radiologically confirmed cholangiocarcinoma Received brachytherapy or stereotactic body radiotherapy (SBRT)

Exclusion criteria

Exclusion criteria: Age < 18 years no additional exclusion criteria

Design outcomes

Primary

Measure	Time frame
local control; Evaluation of local control through a retrospective analysis of follow-up imaging (CT/MRI/PET-CT), which was generally performed every three months. Radiological reports will be reviewed retrospectively, and the imaging studies themselves will also be re-evaluated."	—

Secondary

Measure	Time frame
Disease-specific survival; overall survival	—

Countries

Germany

Contacts

Public ContactFrederik Fuchs

Klinik für Strahlentherapie und Radioonkologie, LMU Klinikum

frederik.fuchs@med.uni-muenchen.de+49 89 440073770

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026